Directory
Price Comparisons
Pharmaceutical Sales
Chantix
ADD/ADHD Drugs
AIDS Drugs
Lunesta, Ambien, Sonata Rozerem
Antidepressants
Antihistamines
ARB's
Arthritis Drugs
Atypical Antipsychotics
Cholesterol Drugs
Cialis
Cialis Blog
Crestor
Diabetes Drugs
Diabetic Supplies
Drug Information Databases
Enzyte
Lamisil
Levitra
Osteoporosis Drugs
Ortho Evra Lawsuit
Pharmaceutical Sales
Pharmacy CE
Strattera
Tramadol
 
Valtrex
Viagra
Viagra Price Comparison
Viagra Information Blog
Vioxx Trial
Whistleblower Law
Xenical
Zyprexa Lawsuit
Investigations
Enzyte
Zestra
Antibiotics without a prescription
Research/Regulatory
Clinical Trial Intell Data
SEARCH Medline
Medline Plus  by Topic
Amedeo
CDER LIst - (FDA)
New Drugs (Center Watch)
FDA
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Upcoming Meetings

Medwatch Safety
Recalls/Alerts
Warning Letters

Medwatch 

***********
Pharmaceutical Blogs:
And cool sites
PharmaGossip Irreverent, often hilarious take on all things pharmaceutical - guaranteed to break the ice at parties [wink, wink, nod, nod]
Viagra For Women; Investigative Report
The Eyes Have It
Mike Havrilla - BioMedReports.com
Canada Pharmacy News
NewHopeBlog.com
PharmaJobsBlog
Drug Wonks
The Healthcare Blog
My HIV story. com
Visual Being
Drug Injury Watch
AdChat
WorldPharmanews
Before You Take That Pill
Pharma Poland
The Science Business
BNET Pharma Beat
ETF Innovators

Additional Pharma News

Internet Drug News'
Medical Abbreviations
Search By Abbreviation
Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here
.

counter to blogspot

Internet Drug News.com online since 1998
Pharmaceutical News & Information; Updated Daily;
See Also: Pharmaceutical Sales | Pharma Advertising Help Wanted | Advertise

Advertisement
 Identify: Determine the key drivers of patient behavior - SDI

Pharmaceutical News Harvest ™
(Click HERE for last Week's News)


7/3 Big JNJ Deal Reduces Elan Debt, May Please Dissident Shareholders
J&J buys $1 bln Elan stake, gains Alzheimer's R&D ... The transaction will give J&J a 25 percent interest in a closely watched Alzheimer's drug called bapineuzumab ... [ Reuters ]

7/3 Multaq Update
Sanofi Ends 7-Year Drought With Approval for Multaq ... Sales of $2.12 billion a year expected by 2015 … drug is also under review by European Medicines Agency ... [ Bloomberg ]

7/3 Essential Hospice Drug Hard to Find
FDA working to ease shortage of morphine for dying patients ... Because of the shortage, compounding pharmacies are mixing a concentrated morphine mixture for some patients, but that has raised the cost and complexity of care ... [ Birmingham (Al.) News ]

7/3 Lucentis Effective for Retinal Vein Occlusion
Roche's Lucentis Improved Vision in Vein Blockage ... Lucentis, marketed for macular degeneration, improved vision after six months compared with a placebo in a study of 397 patients with a blockage in the blood supply to the retina ... [ Bloomberg ]

7/3 NSAID Makers See Chance to Gain Share from Acetaminophen Warnings
Painkiller Dosage: It's J&J vs. Wyeth ... The suggested FDA curb on acetaminophen dosage has set the two companies battling over the relative safety of rival classes of analgesics ... [ BusinessWeek ]

7/3 Bad Plant Spurs Generic Recalls All Over England
U.K. Recalls Generic Drugs After Violations ... Novartis's generics unit was one of about eight companies that recalled drugs this week because of "serious" deficiencies in so-called good manufacturing practices found during inspections of the contract manufacturer, MJ Biopharm, in India ... [ $$WSJ ]

7/3 CMS Wants to Rob Specialists to Pay PCPs
Medicare May Pay More for Primary Care, Less for Procedures ... CMS is proposing a set of tweaks that would raise the fees Medicare pays for primary care by 6% to 8% … Medicare payments to cardiologists would be cut by 11% overall, with certain procedures facing steeper cuts ... [ WSJ Health Blog ]

7/3 PPIs Observed Creating Symptom They Are Supposed to Cure
Rebound Acid Reflux with PPIs May Induce Dependence ... After a two-month course of esomeprazole (Nexium), 44% of asymptomatic, healthy volunteers had clinically significant heartburn, acid reflux, or dyspepsia, compared with 15% who had taken placebo ... [ Medpage Today ]

7/3 A Glimmer of Hope for Multiple-drug Resistant TB
Parkinson's drugs show promise in resistant TB ... Computer programs predicted that tolcapone (Tasmar/Valeant Pharmaceuticals) and entacapone (Comtan/Novartis) should interfere with the TB bacillus, and tests in lab dishes using the drug Comtan confirmed it... [ Reuters ]

7/2 Internet Drug News
Miscellaneous Short Takes:
Celiac Disease Making Inroads in U.S.
HealthDay
Predicting the Return of Prostate Cancer: New Study Betters the Odds of Success
Johns Hopkins Medicine
Two more Seroquel suits dismissed in Delaware
Delaware Online
Graceway buys 3 Pfizer skin drug candidates
AP


     7/2 FDA Questions Validity Of Lantus/Cancer Data
Early Communication About Safety of Lantus (insulin glargine) ... inconsistencies in findings within and across individual studies raise concerns as to whether an association between the use of insulin glargine and cancer truly exists … duration of patient follow-up in all four studies was shorter than what is generally considered necessary to evaluate for cancer risk from drug exposure ... [FDA Communiqué]
V I D E O: Watch now CNBC Report [CNBC Report; Mike Huckman]
See Also: Similar communiqué from the American Diabetes Association
See Also: Similar communiqué from the American College Of Clinical Endocrinologists
Editor's Note: Unusual in that we have 3 credible entities questioning the data.  Investor fears appear to be somewhat allayed; Sanofi shares shot up 2.88% on Thursday (including +0.33% in after-hours trading).

7/2
Chantix and Zyban Get Black Box
Pfizer, Glaxo Smoking Pills Get Warning on Suicides ... The FDA has received a combined 317 reports of suicides and attempted suicides among patients taking the drugs ... [ Bloomberg ]
See also: Popular Stop-Smoking Drugs to Carry Mental Health Risk Warnings [ Medpage Today]

7/2
Multaq Approved With Limits On Use In Severe CHF
Sanofi-Aventis' Multaq Drug Approved By FDAcompany will begin marketing the drug in the U.S. this summer, with limits on use that exclude patients with severe heart failure … potential blockbuster product …[NASDAQ]
Sanofi-Aventis Says FDA Approves Multaq For Patients With Atrial Fibrillation Or Atrial Flutter - Quick Facts
indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation, or AF, or atrial flutter, or AFL, with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted …[RTT]
See Also: Similar Report From Reuters ...adds shares rise 1.7%
See Also: Sanofi Press Release

Advertisement

7/2 Lantus Study Rushed to Press
Sanofi Stock Drop Spurred Rush to Publish Lantus Data ... Sanofi-Aventis's three-day stock decline last week prompted the European Association for the Study of Diabetes to publish research on the French drugmaker's Lantus insulin a week ahead of schedule. ... [ Bloomberg ]

7/2
Drop Your Daily Aspirin and Take a Statin -- BMJ Study
Study Supports Wider Use of Statins ... A meta-analysis of 10 trials involving more than 70,000 participants found that statin therapy reduced overall mortality by 12 percent, major coronary events by 30 percent and strokes by 19 percent ... [ HealthDay ]

7/2
New Partnership Advances Oral MS Treatment
Biogen Buys Rights to Acorda's MS Pill Outside U.S. ... Biogen, based in Cambridge, Massachusetts, is racing Merck KGaA and Novartis AG to market the first pill for MS, a debilitating nervous-system disease currently managed by injected drugs that generate $6 billion a year worldwide ... [ Bloomberg ]

7/2
MA and VT Ban Physician Gifts, Most All Meals
Two States Restrict Firms' Gifts to Doctors ... As of July 1, in Massachusetts and Vermont, pharmaceutical companies and medical-device makers will be banned from giving doctors such gifts as resort trips or even coffee mugs ... [ $$WSJ ]

7/2
Dreaded 'Complete Response' Letter for Menveo
Novartis sees FDA decision on Menveo early 2010 ... Menveo, which the firm wants to sell to adults and adolescents, is one of two Novartis vaccines against meningococcal infection in late-stage development viewed as potential best-sellers ... [ Reuters ]

7/2
Vasotec and Cozaar Protect Ye Diabetic Eyeballs
Blood pressure drugs slow eye problems in diabetes ... Diabetic retinopathy progressed significantly in 38 percent of the volunteers getting a placebo compared to only 25 percent who took enalapril and 21 percent who got losartan. ... [ Reuters ]

7/2
JAMA Pours Cold Water On Crestor Hopes:
CRP Not a Cause of Heart Disease; Don't Medicate It

Findings of Genetics Study Does Not Support Causal Association of C-Reactive Protein With CHD ... Researchers: "this study suggests that development of therapeutic strategies targeting specific reductions in plasma levels of CRP are unlikely to be fruitful" ... [ American Medical Association ]

7/2
Internet Drug News Miscellaneous Short Takes:
U.S. group questions AstraZeneca's Crestor patent
Reuters
AstraZeneca's Iressa gets E.U. marketing authorization
Marketwatch
Discovery Labs says lung drug unlikely to get FDA nod
Reuters
A Combination of Common Genetic Variations Can Lead to Schizophrenia
University of North Carolina at Chapel Hill School of Medicine
Importation amendment dies in utero
Drug Store News
Teva launches version of JNJ birth control pill Ortho Tri-Cyclen
AP

7/1
FDA Panel: Ban Some Combo Acetaminophen Products,
Reduce Maximum Recommended Daily Dose, Make High-Dose Rx Only
OTC Combo Products Get Breathing Room
U.S. advisers call for ban of some pain drugs … voted 20-17 to urge the agency to eliminate such products, which include Vicodin and Percocet …[Reuters]
FDA Panel Recommends Smaller Doses of Painkillers … recommended the maximum daily dose be lowered to 2,600 milligrams from 4,000 milligrams … 500 milligram doses of the drug be available in prescription only …[Wall Street Journal]
FDA Advisers Urge Smaller Doses of Acetaminophen … voted 24-13 to limit the maximum single dose of acetaminophen to 650 milligrams … 26-11 to make the 1,000-milligram dose of acetaminophen available only by prescription … voted against other safety restrictions for other over-the-counter drugs such as NyQuil or Theraflu …[HealthDay]
See Also: Similar Report From NASDAQ

Smells Like Entrée To Therapeutic Substitution; TNF Blockers In Crosshairs
J&J, Abbott, Amgen Drugs Warrant Study, IOM Says … Remicade from J&J, and Enbrel, marketed by Wyeth and Amgen, in a family of medicines linked to cancer …[Bloomberg]
Report: Cost Should Play Role In Comparing Medical Treatments … highest priority recommendations is to study the effectiveness of biologics in treating Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis … [NASDAQ]


7/1 Sleepy Rodents May Hold Key To Ambien Sleep-Eating, Sleep-Driving
Discovery could explain awakenings that occur with Ambien … During an awakening, a person can do all types of normal activities ranging from eating breakfast to driving into work. Most will have no recollection …[ Examiner.com]

7/1
Sutent For Colon Cancer:  Lack Of Efficacy Spurs Pfizer To Stop
Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer … addition of sunitinib to the chemotherapy regimen FOLFIRI would be unable to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival …[Pfizer Press Release]

7/1
FDA Green Lights Injectable Iron Replacement Product
FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients … treatment of iron deficiency anemia in adult patients with chronic kidney disease … recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg IV injection three to eight days later … [AMAG Pharmaceuticals Press Release]
Editor's Note:  Adds that it will be available in 2 weeks; 80-person sales force.

7/1
Experts Debate Interpretation of Lantus Data
Mixed Message on Insulin Glargine Cancer Risk … Studies examining a possible cancer link to insulin glargine (Lantus) produced mixed conclusions that drew quick, reassuring responses from diabetes authorities …[medpage TODAY]
Sanofi Faces Headache Over Studies on Lantus … likely to create a long-term headache for drug giant Sanofi-Aventis SA, even as some medical experts caution that the studies are inconclusive … Investors will likely remain cautious until more data are published…[Wall Street Journal]

7/1
Sanofi Re-Org: Streamline R&D, Voluntary  Separations
Sanofi Revamps R&D to Spur Innovation, Find New Drugs  ...esist the temptation to favor products developed in-house … doesn't plan any layoffs, even as it reduces employment…[Bloomberg]
Sanofi remodels R&D, no forced layoffs … Eight out of 27 R&D sites will close worldwide … focus on diabetes, cancer and age-linked diseases as well as anti-inflammatory and anti-infectious diseases … …[Reuters]

7/1 Multaq Decision Still Up In The Air
Sanofi has not received any U.S. news yet on Multaq … No FDA news yet on experimental heart drug Multaq … Awaiting final marketing decision, no other comment…[Reuters]

7/1
Cephalon Submits Nuvigil For Eastbound (NOT Westbound) Jet Lag
Cephalon Submits NUVIGIL SNDA for Excessive Sleepiness Associated with Jet Lag … indication of improved wakefulness in patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel … 70 million American travelers experience jet lag annually …[Cephalon Press Release]
Editor's Note: That's a curious indication.

7/1
Anti-Angiogenic Drugs Encouraged Metastasis: Who, What, Why
Metastasis: When Good Drugs Do Bad Things … Two papers in Cancer Cell have shown that, despite positive effects on established localized tumours, inhibition of angiogenesis can result in increased tumour invasion and metastasis …[Medscape - Free Reg. Reqd.]

7/1
Internet Drug News Miscellaneous Short Takes:
Pozen Submits Naproxen/ Nexium Combo Pill
RTT
Analyst: Geron Deal Much Ado About Nothing; Good Stock To Short
The Street
FDA Calendar Updates: POZN, AZN , SNY, CEPH, APPY, CYTR
Biomed Reports
The 15 most promising biotech companies
Fierce Biotech
Obama-Proof: Pfizer, Bristol-Myers and Teva
The Street
WHO says Tamiflu-resistant H1N1 "isolated case"
Reuters

6/30
IMS, Verispan, SDI Lose Bid To Block Anti-Doc Data Mining Law
Court denies bid to limit Vt. law on prescription data ...denied a request by three drug data-miners and the Pharmaceutical Research and Manufacturers  ...goes into effect July 1 …[ModernHealthcare.com]
US top court won't review prescription privacy law … Reuters

6/30
Critics: Cancer Drugs Overpriced Relative To Efficacy
Cost-Effectiveness of Cancer Drugs Is Questioned … expensive cancer drugs to prolong patients' lives by just weeks or months was called into question … [Wall Street Journal; $$$]
Lilly Erbitux Cancer Drug Not Worth Price, U.S. Scientists Say … [Bloomberg]
See Also: Above cited article (abstract)

6/30
Critics Refute Data Linking Lantus To Cancer
Sanofi's Lantus Cancer Scare Shows How Enormous Power Lies With Few Experts ...results were provocative but far from convincing ...data are not being championed by a U.S. safety hawk like the Cleveland Clinic's Steve Nissen or FDA's David Graham…[Bnet Pharma]
Sanofi dismissive of "poor quality" Lantus studies … warns against risk from "junk science" … studies highlighting a possible link between cancer and its long-acting insulin drug Lantus for diabetes were "of poor quality" …[Reuters]

                             

6/30
Tysabri: Biogen Reports 13th Incidence Of PML
Biogen Reports a 13th Sick Patient on MS Drug … 10 cases since -- including three this month -- have frustrated Biogen's aim of making Tysabri into a blockbuster drug…[Wall Street Journal; $$$]

6/30
Abbott To Pay JNJ $1.67 Bln: Humira Infringed Anti-TNF Patent
Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories … patent in question relates to the company's anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor…[ JNJ Press Release]

6/30
Drugmakers' Reaction To Possible Acetaminophen Crackdown
Acetaminophen Worries: The End of NyQuil as We Know It? … little difference between the maximum recommended daily dose and a potentially harmful dose … consumers may not know acetaminophen is in their medicine…[Wall Street Journal; FREE]
Drug cos at odds with FDA over acetaminophen risk … acetaminophen-containing products, which were $2.6 billion in 2008 … Instead, the FDA should require approval of nonprescription acetaminophen products before they could be sold…[Reuters]

6/30
Internet Drug News Miscellaneous Short Takes:
Merck Resolves Shipping Delays For Shingles Vaccine Zostavax
NASDAQ
Jury rejects Accutane-made-me-kill-my-girlfriend defense
AP
Denmark finds 1st case of H1N1 resistance to Tamiflu
Reuters
Roche: Tamiflu Still Works Despite One Case of Resistance
Wall Street Journal; FREE
AMAG expects FDA action on anemia drug within days
Reuters
Did Demerol cause Michael Jackson's cardiac arrest and death?
KevinMD

!????? ???? ???  .???? ????

6/29
Former Pfizer Rep's Book To Be Hollywood Movie
Gyllenhaal, Hathaway back for 'Love' … humorous memoir that shined a light on the practices of the pharmaceutical industry … The filmmakers hope to begin shooting in the fall …[HollywoodReporter]
Editor's NoteRead more about Jamie Riedy and the book that made him almost famous and hopefully rich.

6/29
FDA Is Determined To Crack Down On Acetaminophen Hep Tox Risk
US FDA To Discuss Liver Risks With Tylenol,Other Painkillers ...reduce recommended dosing levels, limit the number of pills or liquid in each drug containing acetaminophen, and eliminate medicines that combine acetaminophen with other ingredients .. [NASDAQ]

6/29
Roche Yanks Accutane Over Bowel Disease Lawsuits
Roche Pulls Accutane Off Market After Jury Verdicts … 5,000 personal-injury claims over Accutane … users allege drugmakerafailed to properly warn them the medicine could cause inflammatory bowel disease …pulled off the market in 11 other countries  …[Bloomberg]

6/29 MSL Off-Label Spiel: Research Free Speech Or Marketing Tactic?
Drug Firms' Medical Staffs Say What Salespeople Can't  … pharma companies have the impression if you just hire somebody [with a professional degree] and you call them an MSL, it doesn't matter what they say."…[Wall Street Journal; $$$]
Editor's Note:  Adds that number of sales reps has dropped to 90K in 2008 from 106K in 2006; adds that MSL's earn 50% more than primary care sales reps.

6/29
Takeda; Alogliptin Delayed As Expected Till Q1 2012
Takeda's Diabetes Drug Alogliptin Rejected by FDA …  delayed until March 2012 or later … Takeda expects to take 2 years to submit test results … largely expected after the U.S. Food and Drug Administration (FDA) said in March it wanted more data…[Bloomberg]
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes …[Takeda Press Release]

6/29
Saxagliptin Gets CHMP Thumbs Up
ONGLYZA Receives Positive Opinion From CHMP … positive opinion on ONGLYZA will now be reviewed by the European Commission which has the authority to approve medicines for the European Union … [NASDAQ]

6/29
Sanofi Boss Explains Expansion Plans: 
Generics, Animal, Consumer; No Mega Urge To Mega Merge
Sanofi-Aventis seeks more generic acquisitions … seeking to buy more generic drugs companies as part of broader acquisition plans to seek full control rather than the partnerships ...also expressed interest in expanding its consumer and animal health …[FT.com]

6/29
Long Acting Insulin Analogs Linked To Cancer Risk
Novo Nordisk distances itself from Lantus scare … Lantus and Levemir are both long-acting insulin analogues, but Levemir was launched more recently than Lantus and so was not assessed in the European registry studies….[Reuters]
Sanofi says new data inconclusive on Lantus risk … rumours that a damaging analysis of the product's safety was shortly to be published in a major medical journal … no definitive conclusions on possible cancer link … Company says just been made aware of new data … [Reuters]
See Also:  Sanofi-aventis Stands Behind the Safety of Lantus(R)
See Also:  Novo Nordisk Insulin Analogs Have Proven Safety Profiles

6/29 Delaware Blinks:  Welfare Rx Reimbursement Cut Less Than Threatened
Delaware, Walgreen battle over Medicaid dollars … After two months of talks and even an industry lawsuit, Delaware still plans to reduce the amount it reimburses pharmacies for filling Medicaid prescriptions, though by half as much as it previously intended…[Reuters]

6/29
Murderer Blames Zoloft
Neb. inmate's suit over Zoloft latest in a series ...20-to-40-year sentence and will be eligible for parole in 2022 ...started arguing while having sex because she suggested they have a second child….[Philly.com]

6/29
Internet Drug News Miscellaneous Short Takes:
Smell-Loss Drug Escaped FDA Review Under Homeopathic Label
Bloomberg
Cimzia Wins EU Approval For  Rheumatoid Arthritis
UCB Press Release
SIMPONI Receives Positive Opinion From CHMP for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Schering Plough Press Release
Aclasta Indications expanded in EU
Genetic Engineering & Biotechnology News
Seretide Irish Patent Invalidated
Reuters
Pharmacist Comes To Defense Of Accutane Murderer
Pittsburgh Tribune Review
Dermatologist rips Accutane killing defense
Pittsburgh Post-Gazette
Gilead gets positive nod on cystic fibrosis drug
AP
Black Enterprise Magazine Names Aetna as One of the Best Companies for Diversity
Aetna Press Release
NY Post: Jackson was on Xanax, Dilaudis, Soma, Zoloft, Vicodin, Vistaril, Paxil, Prilosec & Demerol
NY Post
             

************
Advertisement******************
     Attention Pharma: Generate leads for FREE!!!
Add your offers to our database at no cost … Email Publisher
More drug coupons than any other site! <<<
Home | Search DATABASE | Mission Statement | About | Drug Coupons By Therapeutic Class

*****************************************************

Read Our Plain-English Privacy Policy

Copyright 2008 Internet Drug News Inc - all rights reserved
CoreyNahman.com and Pharmaceutical News Harvest
are registered Trademarks of Internet Drug News Inc.

# # # # # # #


Please Note: We respect intellectual property holders' rights.

********************************************************
Our pharmaceutical news index format meets and exceeds fair use guidelines [particularly the portions regarding news commentary]  set forth by the The Digital Millennium Copyright Act of 1998 and accepted copyright and trademark doctrine, case law and Supreme Court precedents.

If you feel that your intellectual property, trademark or copyright is being infringed upon by us, please e-mail the webmaster and we will fix it. 

We guarantee 100% compliance. 
We have not had any problems since our founding in 1999.

********************************************************

Attention To all pharmaceutical sales representatives:

Do not use any of the above information to promote your products unless it has been copy approved; promoting with unapproved materials carries severe penalties including termination and criminal prosecution. 

********************************************************
Note To Visitors:

We never answer drug or health related questions so please don't e-mail us with your drug related questions.

If you have a question about a drug that you are taking or if you think you are experiencing a side effect from a drug that you are taking you must get in touch with the doctor who prescribed the drug or the pharmacist who dispensed it to you,
not us.

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription.   Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

It's foolish to start taking a medicine or stop taking a medicine on your own based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.

Copyright, 2008 Internet Drug News Inc - all rights reserved
CoreyNahman.com and Pharmaceutical News Harvest are registered Trademarks of Internet Drug News Inc.


*****************************************
We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published by Corey Nahman, a registered pharmacist in the Sate of New York.
2. 
Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3. 
Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4.
Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5. 
Justifiability
This site shall at all times back up claims relating to benefits and performance.
Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7. 
Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  You will notice a variety of ads throughout the site from the following advertising partners:

*********************************************
Proudly Published In NEW YORK CITY, USA

Site Map |
Privacy Policy | Contact Webmaster |
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated: 6/29/2009